glp 1 compounding fda Novo asks to prevent compounders from making GLP-1 knockoffs Congress Introduces SAFE Drugs Act

Now, input the volume of bacteriostatic water you plan to add to the vial to reconstitute the peptide

This tiny addition is a game-changer

Swirl the vial gently until the solution is completely clear and the dual-peptide matrix is fully dissolved

It is non-irritating for most skin types and provides excellent antioxidant protection

Sources Novo Nordisk NDA filing for CagriSema, December 18, 2025 American Diabetes Association REDEFINE-1 and REDEFINE-2 results, ADA 2026 Scientific Sessions HCPLive REDEFINE-1 Phase 3 safety and efficacy data Clinical Trials Arena REDEFINE-4: CagriSema vs tirzepatide head-to-head, February 2026 Life Science Daily News CagriSema FDA review timeline and NDA update, July 2026 PharmExec REDEFINE-1 results: CagriSema falls short of 25% weight loss target Drugs.com CagriSema FDA approval status history New England Journal of Medicine REDEFINE-1 full publication (presented at ADA 2026) Novo Nordisk REIMAGINE Phase 3 diabetes trial results, ADA 2026 and The Lancet FDA Wegovy (semaglutide) prescribing information, 2025 Related reading on Heally: What is Wegovy HD